# New Biocalysis Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/new-biocalysis-technology

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.hzymes.com
- Total disclosed funding: $125M
- Latest round: Series C (Nov 5, 2021)
- Investors on record: 8

## About

Established in 2015 and based in Wuhan, China, New Biocalysis Technology is a company focusing on the research and development, production, and technology of raw materials for bio-pharmaceutical and IVD industry. 

The company has developed more than 100 raw materials of IVD reagents, its IVD products are used in bio-pharmaceutical, vaccine production, molecular diagnosis, and bio-sensing etc. The company is in partnership with over 100 IVD reagent manufacturers, and selling the products to 25 countries.

## Funding rounds

- Series C, Nov 5, 2021, $125M — CASH Capital, State Science & Technology Investment, GL Capital Group, Ciit Asset Management, GF Qianhe, Guangzhou Tianhui Capital Management, Zexian investment, Guokai Kechuang

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series C
- State Science & Technology Investment (https://capitalatlas.ai/funds/state-science-technology-investment) — Series C
- GL Capital Group (https://capitalatlas.ai/funds/gl-capital-group) — Series C
- Ciit Asset Management (https://capitalatlas.ai/funds/ciit-asset-management) — Series C
- GF Qianhe — Series C
- Guangzhou Tianhui Capital Management — Series C
- Zexian investment — Series C
- Guokai Kechuang — Series C